Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with DTC, sorafenib exposure and the incidence of some adverse events (AEs) were higher tha...

Full description

Bibliographic Details
Main Authors: Joachim Grevel, Garrit Jentsch, Rupert Austin, Nicolaas H. Prins, John Lettieri, David Mitchell, Funan Huang, Marcia S. Brose, Martin Schlumberger, Gerold Meinhardt, Carol E. A. Peña, Bart A. Ploeger
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.12634

Internet

https://doi.org/10.1111/cts.12634

Similar Items